Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Clin Exp Obstet Gynecol ; 33(3): 159-63, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17089580

RESUMO

Cord blood, because of its rich mix of fetal and adult hemoglobin, high platelet and white blood cell (WBC) counts, and a plasma filled with cytokine and growth factors, as well as its hypoantigenic nature and altered metabolic profile, has all the potential of a real and safe alternative to adult blood transfusion. Our experience of 74 units (50 ml-146 ml mean, 86 ml +/- 7.6 ml SD, median 80 ml, mean packed cell volume 48 +/- 4.1 SD, mean percent hemoglobin concentration 16.2 g/dl +/- 1.8 g/dl of placental umbilical cord whole blood collection (from 1 April 1999) after lower uterine cesarean section (LUCS) from consenting mothers and transfusion of the same to 16 informed, consenting patients with percent plasma hemoglobin 8 g/dl or less, is presented here. After collection the blood was immediately preserved in the refrigerator and transfused within 72 hours of collection. Fifteen males and one female, aged 12-72 yrs (mean 48.4 yrs) participated: five cases were pausibacillary type (PB) and 11 cases were multibacillary type (MB). The clinical spectrum of the cases varied widely from the tuberculoid to the lepromatous type and one patient presented with gangrene of the leg preceding an auto amputation which was infested with maggots. Each case was approved by the institutional ethical committee and received two to eight units of freshly collected placental umbilical cord blood in one transfusion without encountering any clinical, immunological or non-immunological reaction. Seven days after completion of the placental umbilical cord blood transfusion, the peripheral blood hematopoietic stem cell (CD34) estimation revealed a rise from the pretransfusion base level (.09%), varying from 3.6% to 16.2%, in 75% of the cases, without provoking any clinical graft vs host reaction in any of the leprosy victims. This value returned to normal within three months in most cases.


Assuntos
Anemia/terapia , Transfusão de Sangue/métodos , Sangue Fetal/transplante , Células-Tronco Hematopoéticas/metabolismo , Hanseníase/complicações , Adolescente , Adulto , Idoso , Anemia/sangue , Anemia/complicações , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Gravidez , Resultado do Tratamento
2.
Med Oncol ; 19(2): 79-86, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12180484

RESUMO

We conducted a nonrandomized prospective phase II study of thalidomide in anemic patients with myelofibrosis with myeloid metaplasia (MMM), with or without preceding polycythemia vera or essential thrombocythemia, with a primary aim to improve anemia. Thalidomide was given in escalating doses with a target dose of 800 mg daily, but the median dose of thalidomide that was actually tolerated was 400 mg daily. Fifteen patients were entered into the study and 14 were evaluable for response. Five of 14 (36%) patients discontinued thalidomide before 3 mo because of side effects, and none of these five patients had a response at the time when thalidomide was stopped. When evaluated after 3 mo of therapy, none of the remaining nine patients exhibited a discernible clinical response. Three patients showed progressive disease defined as > 50% increase in the need for red cell transfusions. Treatment was poorly tolerated, with all patients reporting side effects of thalidomide, the most prominent being fatigue documented in 80% of patients. Two patients died while on study, one from acute myelogenous leukemia and one from pneumonia. We conclude that thalidomide given in doses employed in the treatment of multiple myeloma gives no clinically relevant hematological effects in advanced MMM and is hampered by a very high incidence of side effects.


Assuntos
Anemia/complicações , Hansenostáticos/efeitos adversos , Mielofibrose Primária/tratamento farmacológico , Talidomida/efeitos adversos , Adulto , Idoso , Anemia/tratamento farmacológico , Anemia/terapia , Transfusão de Sangue , Medula Óssea/efeitos dos fármacos , Feminino , Humanos , Hansenostáticos/administração & dosagem , Hansenostáticos/uso terapêutico , Masculino , Pessoa de Meia-Idade , Mielofibrose Primária/complicações , Baço/efeitos dos fármacos , Talidomida/administração & dosagem , Talidomida/uso terapêutico , Falha de Tratamento
3.
Clin Lab Haematol ; 22(6): 329-36, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11318798

RESUMO

We studied a recessive hereditary spherocytosis (HS) family from Norway in which all four children had haemolytic spherocytosis while spectrin (Sp) deficiency was detected in the proband. Molecular analysis demonstrated that all affected children had inherited the low expression alpha-Sp allele LEPRA (Low Expressed PRAgue) from the father. Haplotyping with a polymorphic dinucleotide repeat for the alpha-Sp gene (alphaVNTR) located in the 3' untranslated region of mRNA showed that all recessive children had inherited the same maternal alpha-spectrin allele. The paternal Sp-alphaLEPRA allele was found in cis of the polymorphic alpha-Sp Bughill allele (alphaBH) characterized by the A970D point mutation in the Sp alpha-chain. This mutation was identified on two-dimensional electrophoresis of Sp tryptic digests as an acidic shift of the alphaII tryptic domains (spots alphaIIa). Analyses of the relative expression of the paternal alpha-Sp Bughill polymorphism in the proband showed that the product of the maternal alpha-Sp gene is almost completely absent from the mature erythrocyte membrane. Comparative analysis between alphaVNTR PCR-amplified from genomic DNA and from cDNA showed that the maternal low expression alpha-Sp allele is associated with a decreased amount of mRNA. Results from molecular and biochemical studies showed that all the affected children of this family are compound heterozygous for two different low expression alpha-Sp alleles: an uncharacterized defective alpha-Sp allele on the maternal side and an alphaLEPRA allele tagged by the alphaIIa polymorphism on the paternal side.


Assuntos
Genes Recessivos , Espectrina/genética , Esferocitose Hereditária/genética , Anemia/genética , Anemia/terapia , Pré-Escolar , Doenças em Gêmeos/genética , Transfusão Total , Feminino , Humanos , Hiperbilirrubinemia/genética , Hiperbilirrubinemia/terapia , Lactente , Masculino , Linhagem , Fototerapia , Espectrina/deficiência , Esferocitose Hereditária/sangue , Gêmeos Dizigóticos/genética
4.
Masui ; 46(5): 700-3, 1997 May.
Artigo em Japonês | MEDLINE | ID: mdl-9185472

RESUMO

A 79-year-old woman had her cervical spinal cord injured and laminoplasty of the neck was performed. Uncontrollable venous bleeding was encountered during the operation and about 5000 ml of blood was lost in one hour. Massive infusion of 5% albumin and hydroxyethylstarch (HES) was done to maintain the intravascular volume. Therefore, her hematocrit value (Ht) decreased to 4.5%. Her rectal temperature went down to 34.5 degrees C. The operation was finished in haste. We studied leg pain experienced under spinal anesthesia in leprosy patients. Seven of twenty patients complained of the leg pain a few minutes after spinal block. The pain was localized in the parts of deafferentation or phantom limb, and was relatively mild and controllable. We consider that the inhibitory system is inactivated when the somatic impulse is blocked by spinal anesthesia, and as a result the abnormal burst activity of dorsal horn produced by peripheral nerve damage of leprosy causes phantom pain.


Assuntos
Anemia/terapia , Perda Sanguínea Cirúrgica , Transfusão de Sangue , Complicações Intraoperatórias/terapia , Idoso , Feminino , Hematócrito , Hemodiluição/efeitos adversos , Humanos , Hipotermia Induzida/efeitos adversos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA